Table 2.
Characteristics of index therapy treatment
| Treatment characteristics | FTD/TPI, n = 126 | Regorafenib, n = 95 | p value |
|---|---|---|---|
| Year of treatment initiation, n (%) | |||
| 2012 | 1 (0.8) | 16 (16.8) | <.001 a |
| 2013 | 1 (0.8) | 22 (23.2) | <.001 a |
| 2014 | 0 (0.0) | 27 (28.4) | <.001 a |
| 2015 | 44 (34.9) | 14 (14.7) | <.001 a |
| 2016 | 49 (38.9) | 7 (7.4) | <.001 a |
| 2017 | 31 (24.6) | 9 (9.5) | .004 a |
| Time from mCRC diagnosis to start of therapy mean ± SD (median), mo | 34.0 ± 25.1 (27.8) | 31.3 ± 19.4 (29.2) | .863 |
| Follow‐up time from index therapy mean ± SD (median), mo | 9.2 ± 6.7 (7.1) | 8.5 ± 7.6 (6.3) | .157 |
| Treatment setting, n (%) | |||
| Clinical trial | 4 (3.2) | 0 (0.0) | .136 |
| Standard of care | 116 (92.1) | 95 (100.0) | .006 a |
| Compassionate use | 5 (4.0) | 0 (0.0) | .072 |
| Unknown | 1 (0.8) | 0 (0.0) | |
| Line of index therapy, n (%) | |||
| 2nd | 8 (6.3) | 4 (4.2) | .487 |
| 3rd | 39 (31.0) | 29 (30.5) | .946 |
| 4th | 36 (28.6) | 22 (23.2) | .365 |
| 5th | 26 (20.6) | 22 (23.2) | .652 |
| 6th plus | 17 (13.5) | 18 (18.9) | .271 |
| Patients with dosing information, n (%) | 119 (94.4) | 92 (96.8) | |
| First prescription dose, mean ± SD (median), mg/day | 118.9 ± 27.3 (120.0) | 142.2 ± 76.5 (160.0) | |
| Dosing patterns, patient level | |||
| Dose intensity, mean ± SD (median), mg/day | 117.5 ± 25.9 (120.0) | 132.3 ± 66.9 (120.0) | .010 a |
| Label recommended dose, mean ± SD (median), mg/day | 130.8 ± 20.0 (130.4) | 160.0 ± 0.0 (160.0) | |
| Relative dose intensity, mean ± SD (median) | 0.9 ± 0.2 (1.0) | 0.8 ± 0.4 (0.8) | <.001 a |
| Patients with no dose modifications, n (%) | 100 (84.0) | 59 (64.1) | <.001 a |
| Dose modifications per patient, mean ± SD | 0.2 ± 0.5 | 0.4 ± 0.6 | .001 a |
a
p value <.05.
Abbreviations: FTD/TPI, trifluridine/tipiracil; mCRC, metastatic colorectal cancer.